This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

10.3% of XBI Holdings Seeing Recent Insider Buys

A look at the weighted underlying holdings of the SPDR S&P Biotech ETF (XBI) shows an impressive 10.3% of holdings on a weighted basis have experienced insider buying within the past six months.

10 ETFs With Stocks That Insiders Are Buying »

Merrimack Pharmaceuticals Inc. (MACK), which makes up 1.19% of the SPDR S&P Biotech ETF (XBI), has seen 6 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $13,397,309 worth of MACK, making it the #51 largest holding. The table below details the recent insider buying activity observed at MACK:

MACK — last trade: $7.04 — Recent Insider Buys:

Purchased Insider Title Shares Price/Share Value
05/05/2014 Michael E. Porter Director 15,000 $6.41 $96,150.00
05/05/2014 Gary L. Crocker Director 10,000 $6.69 $66,900.00
05/05/2014 Robert J. Mulroy President and CEO 5,000 $6.31 $31,550.00
05/06/2014 Gary L. Crocker Director 17,500 $6.89 $120,575.00
05/05/2014 Michael E. Porter Director 5,000 $6.12 $30,600.00
05/07/2014 Gary L. Crocker Director 4,400 $6.77 $29,788.00
05/07/2014 Sarah E. Nash Director 15,000 $6.79 $101,850.00
05/08/2014 Michael E. Porter Director 10,000 $6.59 $65,900.00
05/13/2014 Anthony J. Sinskey Director 5,000 $6.74 $33,700.00
05/16/2014 Michael E. Porter Director 15,000 $6.49 $97,400.00
05/19/2014 Gary L. Crocker Director 9,400 $6.68 $62,802.00
05/19/2014 James H. Quigley Director 5,000 $6.58 $32,900.00
05/20/2014 Gary L. Crocker Director 4,000 $6.69 $26,760.00
06/23/2014 Michael E. Porter Director 32,390 $6.84 $221,547.60
06/23/2014 Gary L. Crocker Director 36,000 $6.84 $246,240.00

And Synergy Pharmaceuticals Inc (SGYP), the #58 largest holding among components of the SPDR S&P Biotech ETF (XBI), shows 4 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $12,889,101 worth of SGYP, which represents approximately 1.14% of the ETF's total assets at last check. The recent insider buying activity observed at SGYP is detailed in the table below:

SGYP — last trade: $3.58 — Recent Insider Buys:

Purchased Insider Title Shares Price/Share Value
05/23/2014 Bernard Denoyer Senior Vice President, Finance 2,500 $3.89 $9,725.00
05/23/2014 Kunwar Shailubhai Chief Scientific Officer 3,000 $3.89 $11,670.00
05/27/2014 Gary S. Jacob Chief Executive Officer 4,000 $4.18 $16,720.00
06/03/2014 John P. Brancaccio Director 3,500 $4.12 $14,420.00

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs